Erdafitinib: First Global Approval

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

(2018) Arlene O. Siefker-Radtke et al.   JOURNAL OF CLINICAL ONCOLOGY

920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study

(2018) Y Loriot et al.   ANNALS OF ONCOLOGY

624PDPreliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA)

(2018) Y-Y Chen et al.   ANNALS OF ONCOLOGY

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

(2017) Tomohiro Nishina et al.   INVESTIGATIONAL NEW DRUGS

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

(2017) Jayaprakash D. Karkera et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

(2017) Timothy P.S. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma

(2016) J. Tabernero et al.   ANNALS OF ONCOLOGY

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY